A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Numerous clinical conditions can lead to organ fibrosis and functional failure. There is a great need for therapies that could effectively target pathophysiological pathways involved in fibrosis. GPR40 and GPR84 are G protein-coupled receptors with free fatty acid ligands and are associated with metabolic and inflammatory disorders. Although GPR40 and GPR84 are involved in diverse physiological processes, no evidence has demonstrated the relevance of GPR40 and GPR84 in fibrosis pathways. Using PBI-4050 (3-pentylbenzeneacetic acid sodium salt), a synthetic analog of a medium-chain fatty acid that displays agonist and antagonist ligand affinity toward GPR40 and GPR84, respectively, we uncovered an antifibrotic pathway involving these receptors. In experiments using Gpr40- and Gpr84-knockout mice in models of kidney fibrosis (unilateral ureteral obstruction, long-term post-acute ischemic injury, and adenine-induced chronic kidney disease), we found that GPR40 is protective and GPR84 is deleterious in these diseases. Moreover, through binding to GPR40 and GPR84, PBI-4050 significantly attenuated fibrosis in many injury contexts, as evidenced by the antifibrotic activity observed in kidney, liver, heart, lung, pancreas, and skin fibrosis models. Therefore, GPR40 and GPR84 may represent promising molecular targets in fibrosis pathways. We conclude that PBI-4050 is a first-in-class compound that may be effective for managing inflammatory and fibrosis-related diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541
Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40
Itoh, Y., Kawamata, Y., Harada, M., Kobayashi, M., Fujii, R., Fukusumi, S., Ogi, K., Hosoya, M., Tanaka, Y., Uejima, H., et al. (2003) · Nature · doi:10.1038/nature01478 · Cited by 1,538
Edfalk, S., Steneberg, P., & Edlund, H. (2008) · Diabetes · doi:10.2337/db08-0307 · Cited by 587
A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs
Kotarsky, K., Nilsson, N. E., Flodgren, E., Owman, C., & Olde, B. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)03064-4 · Cited by 352
Burant, C. F., Viswanathan, P., Marcinak, J., Cao, C., Vakilynejad, M., Xie, B., & Leifke, E. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61879-5 · Cited by 244
Cited by
Targeting metabolic dysregulation for fibrosis therapy
Zhao, X., Kwan, J. Y. Y., Yip, K., Liu, P. P., & Liu, F.-F. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0040-5 · Cited by 513
Savin, I. A., Zenkova, M. A., & Sen’kova, A. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314959 · Cited by 279
Mitochondria dysfunction and metabolic reprogramming as drivers of idiopathic pulmonary fibrosis
Bueno, M., Calyeca, J., Rojas, M., & Mora, A. L. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101509 · Cited by 275
The therapy of idiopathic pulmonary fibrosis: what is next?
Somogyi, V., Chaudhuri, N., Torrisi, S. E., Kahn, N., Müller, V., & Kreuter, M. (2019) · European Respiratory Review · doi:10.1183/16000617.0021-2019 · Cited by 265
Idiopathic pulmonary fibrosis.
Koudstaal, T., & Wijsenbeek, M. S. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104166 · Cited by 105
Metadata
- Authors
- Gagnon, L., Leduc, M., Thibodeau, J.-F., Zhang, M.-Z., Grouix, B., Sarra-Bournet, F., Gagnon, W., Hince, K., Tremblay, M., Geerts, L., Kennedy, C. R. J., Hébert, R. L., Gutsol, A., Holterman, C. E., Kamto, E., Gervais, L., Ouboudinar, J., Richard, J., Felton, A., Laverdure, A., Simard, J.-C., Létourneau, S., Cloutier, M.-P., Leblond, F. A., Abbott, S. D., Penney, C., Duceppe, J.-S., Zacharie, B., Dupuis, J., Calderone, A., Nguyen, Q. T., Harris, R. C., & Laurin, P.
- Venue
- The American Journal of Pathology
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 188
- Issue
- 5
- Pages
- 1132-1148
- ISSN
- 0002-9440 (ISSN-L)
- OpenAlex
- W2785444851
- Cited by
- 138
- References
- 5
- FWCI
- 11.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors. https://app.cochat.ai/papers/10.1016/j.ajpath.2018.01.009
- The paper
- Gagnon, L., Leduc, M., Thibodeau, J.-F., Zhang, M.-Z., Grouix, B., Sarra-Bournet, F., Gagnon, W., Hince, K., Tremblay, M., Geerts, L., Kennedy, C. R. J., Hébert, R. L., Gutsol, A., Holterman, C. E., Kamto, E., Gervais, L., Ouboudinar, J., Richard, J., Felton, A., . . . Laurin, P. (2018). A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors. The American Journal of Pathology. https://doi.org/10.1016/j.ajpath.2018.01.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.